Cambridge Investment Research Advisors, Inc. Vertex Pharmaceuticals Inc Transaction History

Cambridge Investment Research Advisors, Inc.

$29.4 Billion
Q3 2024

A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 14,517 shares of VRTX stock, worth $5.96 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

14,517

Previous 13,923 4.27%

Holding current value

$5.96 Million

Previous $6.53 Million 3.46%

% of portfolio

0.02%

Previous 0.02%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 28, 2024	BUY	$460.0 - $505.78 $273,240 - $300,433	594 Added 4.27%	14,517 $6.75 Million
Q2 2024 Jul 26, 2024	SELL	$392.81 - $485.53 $1.87 Million - $2.31 Million	-4,752 Reduced 25.45%	13,923 $6.53 Million
Q1 2024 Apr 24, 2024	BUY	$407.69 - $446.08 $1.15 Million - $1.25 Million	2,813 Added 17.73%	18,675 $7.81 Million
Q4 2023 Feb 09, 2024	BUY	$343.0 - $410.68 $961,429 - $1.15 Million	2,803 Added 21.46%	15,862 $6.45 Million
Q3 2023 Oct 24, 2023	BUY	$338.18 - $362.46 $7,101 - $7,611	21 Added 0.16%	13,059 $4.54 Million
Q2 2023 Jul 13, 2023	BUY	$314.42 - $351.91 $143,061 - $160,119	455 Added 3.62%	13,038 $4.59 Million
Q1 2023 May 11, 2023	SELL	$283.23 - $323.1 $247,543 - $282,389	-874 Reduced 6.49%	12,583 $3.97 Million
Q4 2022 Feb 08, 2023	SELL	$285.76 - $321.48 $284,331 - $319,872	-995 Reduced 6.88%	13,457 $3.89 Million
Q3 2022 Oct 17, 2022	BUY	$273.83 - $305.53 $123,223 - $137,488	450 Added 3.21%	14,452 $4.18 Million
Q2 2022 Jul 13, 2022	BUY	$234.96 - $292.55 $247,882 - $308,640	1,055 Added 8.15%	14,002 $3.95 Million
Q1 2022 May 12, 2022	BUY	$221.42 - $260.97 $167,836 - $197,815	758 Added 6.22%	12,947 $3.38 Million
Q4 2021 Feb 03, 2022	SELL	$177.01 - $223.45 $7,965 - $10,055	-45 Reduced 0.37%	12,189 $2.68 Million
Q3 2021 Nov 02, 2021	SELL	$181.39 - $202.99 $188,282 - $210,703	-1,038 Reduced 7.82%	12,234 $2.22 Million
Q2 2021 Aug 10, 2021	BUY	$187.49 - $221.1 $204,926 - $241,662	1,093 Added 8.97%	13,272 $2.68 Million
Q1 2021 May 07, 2021	BUY	$207.02 - $241.31 $605,119 - $705,349	2,923 Added 31.58%	12,179 $2.62 Million
Q4 2020 Feb 04, 2021	BUY	$207.01 - $276.09 $89,842 - $119,823	434 Added 4.92%	9,256 $2.19 Million
Q3 2020 Oct 29, 2020	SELL	$255.65 - $303.1 $3.33 Million - $3.95 Million	-13,026 Reduced 59.62%	8,822 $2.4 Million
Q2 2020 Jul 27, 2020	BUY	$225.48 - $295.8 $2.53 Million - $3.32 Million	11,228 Added 105.73%	21,848 $6.34 Million
Q1 2020 May 08, 2020	BUY	$199.77 - $247.81 $412,924 - $512,223	2,067 Added 24.17%	10,620 $2.53 Million
Q4 2019 Feb 04, 2020	BUY	$166.71 - $223.91 $195,884 - $263,094	1,175 Added 15.93%	8,553 $1.87 Million
Q3 2019 Nov 06, 2019	SELL	$166.23 - $187.09 $3,324 - $3,741	-20 Reduced 0.27%	7,378 $1.25 Million
Q2 2019 Aug 15, 2019	BUY	$164.61 - $190.37 $8,888 - $10,279	54 Added 0.74%	7,398 $0
Q1 2019 May 08, 2019	BUY	$163.73 - $194.7 $46,008 - $54,710	281 Added 3.98%	7,344 $0
Q4 2018 Feb 05, 2019	SELL	$151.91 - $192.21 $60,612 - $76,691	-399 Reduced 5.35%	7,063 $1.17 Million
Q3 2018 Nov 02, 2018	BUY	$167.73 - $192.74 $243,376 - $279,665	1,451 Added 24.14%	7,462 $0
Q2 2018 Aug 10, 2018	BUY	$145.72 - $169.96 $10,200 - $11,897	70 Added 1.18%	6,011 $0
Q1 2018 May 09, 2018	SELL	$151.6 - $177.13 $58,062 - $67,840	-383 Reduced 6.06%	5,941 $0
Q4 2017 Feb 22, 2018	SELL	$137.28 - $155.55 $178,601 - $202,370	-1,301 Reduced 17.06%	6,324 $0
Q3 2017 Nov 07, 2017	BUY	$148.13 - $162.24 $183,977 - $201,502	1,242 Added 19.46%	7,625 $1.16 Million
Q2 2017 Aug 08, 2017	BUY	N/A	6,383	6,383 $823,000

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

221M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $105B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.

Account

Cambridge Investment Research Advisors, Inc. Vertex Pharmaceuticals Inc Transaction History